Laidlaw initiates coverage on Senti Biosciences stock with buy rating

On Friday, Laidlaw analysts initiated coverage on Senti Biosciences, Inc. (NASDAQ:SNTI) with a Buy rating and set a price target of $15.00, representing significant upside from the current price of $3.56. The $90.6 million market cap company, which has seen its shares rise 13.4% in the past week, is focused on developing a novel CAR-NK therapy, SENTI-202, for the treatment of relapsed or refractory acute myeloid leukemia (r/r AML).

Senti Biosciences, an early to mid-clinical stage biotechnology firm, recently reported promising interim results from its Phase I trial at the American Association for Cancer Research (AACR) meeting. While the company maintains a healthy current ratio of 4.22, indicating strong liquidity, InvestingPro analysis reveals it’s quickly burning through cash. The company is expected to release further data in 2025 and 2026.

Senti Biosciences is concentrating on oncology, with SENTI-202 being a key part of its therapeutic pipeline. The therapy is designed to offer a differentiated approach to treating high-risk r/r AML patients.

The Laidlaw analysts expressed optimism about the potential of SENTI-202, citing its novel approach to cancer treatment as a significant factor in their positive outlook. The analysts’ 12-month price target reflects their confidence in the company’s future developments and clinical advancements.

In other recent news, Senti Biosciences has reported positive preliminary results from its Phase 1 clinical trial of SENTI-202, a treatment for relapsed or refractory hematologic malignancies, including acute myeloid leukemia (AML). The trial revealed no dose-limiting toxicities and suggested a recommended Phase 2 dose, with several patients achieving complete remission. Additionally, Senti Biosciences disclosed preliminary financial results for the first quarter of 2025, showing cash and cash equivalents of approximately $33.8 million and a net loss of $14.1 million. The company also announced the addition of Dr. James B. Trager to its Scientific Advisory Board, bringing extensive experience in cellular therapy development for cancer. Furthermore, Senti Biosciences has joined Webull’s Corporate Connect Service to enhance communication with shareholders and potential investors. Senti Biosciences has also appointed Feng Hsiung to its Board of Directors, bringing valuable insights from his background in business and finance. The company granted stock options to three new employees, including Jay Cross, the new Chief Financial Officer. These developments highlight Senti Biosciences’ ongoing efforts in advancing its clinical programs and strengthening its leadership team.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.